A promising phase 1 trial with patients with refractory Hodgkin lymphoma underscores the potential value of allogeneic natural killer (NK) cell therapy guided by NK cell-specific engagers.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Herrera, A. F. et al. N. Engl. J. Med. 391, 1379–1389 (2024).
Younes, A. et al. J. Clin. Oncol. 30, 2183–2189 (2012).
Gauthier, J. et al. Blood 137, 323–335 (2021).
Horwitz, S. et al. Lancet 393, 229–240 (2019).
Nieto, Y. et al. Nat. Med. https://doi.org/10.1038/s41591-025-03640-8 (2025).
Kerbauy, L. N. et al. Clin. Cancer Res. 27, 3744–3756 (2021).
Gauthier, L. et al. Cell 177, 1701–1713.e1716 (2019).
Giang, K. A. et al. Nat. Biotechnol. 77, 139–148 (2023).
Demaria, O. et al. Sci. Immunol. 9, eadp3720 (2024).
Bednarski, J. J. et al. Blood 139, 1670–1683 (2022).
Haroun-Izquierdo, A. et al. J. Immunother. Cancer 10, e005577 (2022).
Ghobadi, A. et al. Lancet 405, 127–136 (2025).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.-J.M. has received research support from Oncopeptides for work related to immune engagers. All relationships have been approved by Oslo University Hospital, University of Oslo, Norway and Karolinska Institute, Stockholm, Sweden.
Rights and permissions
About this article
Cite this article
Sohlberg, E., Malmberg, KJ. The innate power of natural killer cells in cancer therapy. Nat Med 31, 1755–1756 (2025). https://doi.org/10.1038/s41591-025-03712-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03712-9
